News Story: Full Text
Sponsored By
AbbVie
Please Click On The Above Banner For More Details
Braintumor Website

 

Metformin Treatment Inhibits Motility and Invasion of Glioblastoma Cancer Cells.

Al's Comment:

This study shows that Metformin MIGHT be useful to help other treatments work better. We know that by itself it is not going to cure a brain tumor, but the evidence shows it inhibits motility and invasion at least in the test tube.  Might be good to watch how it interacts with other treatments in the virtual trial


Posted on: 07/27/2018

Anal Cell Pathol (Amst). 2018 Jun 26;2018:5917470. doi: 10.1155/2018/5917470. eCollection 2018.
Metformin Treatment Inhibits Motility and Invasion of Glioblastoma Cancer Cells.
Al Hassan M1, Fakhoury I1, El Masri Z1, Ghazale N1, Dennaoui R1, El Atat O1, Kanaan A2, El-Sibai M1.
 
Author information:
1. Department of Natural Sciences, School of Arts and Sciences, Lebanese American University, Beirut, Lebanon.
2. Department of Biomedical Sciences, Faculty of Medicine and Medical Sciences, University of Balamand, El-Kurah, Lebanon.
Abstract
 
Glioblastoma multiforme (GBM) is one of the most common and deadliest cancers of the central nervous system (CNS). GBMs high ability to infiltrate healthy brain tissues makes it difficult to remove surgically and account for its fatal outcomes. To improve the chances of survival, it is critical to screen for GBM-targeted anticancer agents with anti-invasive and antimigratory potential. Metformin, a commonly used drug for the treatment of diabetes, has recently emerged as a promising anticancer molecule. This prompted us, to investigate the anticancer potential of metformin against GBMs, specifically its effects on cell motility and invasion. The results show a significant decrease in the survival of SF268 cancer cells in response to treatment with metformin. Furthermore, metformin's efficiency in inhibiting 2D cell motility and cell invasion in addition to increasing cellular adhesion was also demonstrated in SF268 and U87 cells. Finally, AKT inactivation by downregulation of the phosphorylation level upon metformin treatment was also evidenced. In conclusion, this study provides insights into the anti-invasive antimetastatic potential of metformin as well as its underlying mechanism of action.
PMCID: PMC6038689
PMID: 30046513
Similar articles 

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740